Hamish McAllister-Williams

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2378330/publications.pdf

Version: 2024-02-01

75 papers

4,187 citations

172457 29 h-index 63 g-index

75 all docs 75 docs citations

75 times ranked 5232 citing authors

#	Article	IF	CITATIONS
1	Connectivity-Guided Theta Burst Transcranial Magnetic Stimulation Versus Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Moderate to Severe Depression: Magnetic Resonance Imaging Protocol and SARS-CoV-2–Induced Changes for a Randomized Double-blind Controlled Trial. IMIR Research Protocols, 2022, 11, e31925.	1.0	3
2	When depression is difficult to treat. European Neuropsychopharmacology, 2022, 56, 89-91.	0.7	9
3	Cognitive function after electroconvulsive therapy for depression: relationship to clinical response. Psychological Medicine, 2021, 51, 1647-1656.	4.5	12
4	Assessment for vagus nerve stimulation in patients with difficult-to-treat depression: a model from the Newcastle Regional Affective Disorders Service (RADS). Journal of Affective Disorders, 2021, 280, 315-318.	4.1	11
5	Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry,the, 2021, 8, 14-15.	7.4	19
6	The  difficult-to-treat depression' and the  response paradigm' models: Implications and relevance to patient management. Australian and New Zealand Journal of Psychiatry, 2021, 55, 824-825.	2.3	1
7	Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). BMC Psychiatry, 2021, 21, 334.	2.6	2
8	The association between sleep and cognitive abnormalities in bipolar disorder. Psychological Medicine, 2020, 50, 125-132.	4.5	33
9	Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND). BMJ Open, 2020, 10, e038430.	1.9	7
10	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 2020, 267, 264-282.	4.1	133
11	The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. International Journal of Bipolar Disorders, 2020, 8, 13.	2.2	20
12	Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy. Journal of Psychopharmacology, 2019, 33, 1003-1014.	4.0	8
13	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. American Journal of Psychiatry, 2019, 176, 966-966.	7.2	9
14	Bipolar and psychotic disorders in elite athletes: a narrative review. British Journal of Sports Medicine, 2019, 53, 746-753.	6.7	42
15	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry, 2019, 214, 27-35.	2.8	54
16	Multiple-therapy-resistant major depressive disorder: a clinically important concept. British Journal of Psychiatry, 2018, 212, 274-278.	2.8	28
17	Sleep and circadian rhythm disturbance in bipolar disorder. Psychological Medicine, 2017, 47, 1678-1689.	4.5	84
18	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. Journal of Psychopharmacology, 2017, 31, 519-552.	4.0	166

#	Article	IF	CITATIONS
19	Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry,the, 2017, 4, 365-377.	7.4	82
20	Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists. Journal of Affective Disorders, 2017, 207, 346-352.	4.1	18
21	The interrelationship between attentional and executive deficits in major depressive disorder. Acta Psychiatrica Scandinavica, 2016, 134, 73-82.	4.5	29
22	Altered hippocampal function in major depression despite intact structure and resting perfusion. Psychological Medicine, 2016, 46, 2157-2168.	4.5	14
23	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry,the, 2016, 3, 117-127.	7.4	30
24	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2016, 30, 495-553.	4.0	755
25	Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 2016, 17, 86-128.	2.6	204
26	Test–retest reliability and task order effects of emotional cognitive tests in healthy subjects. Cognition and Emotion, 2016, 30, 1247-1259.	2.0	21
27	Neurocognitive intra-individual variability in mood disorders: effects on attentional response time distributions. Psychological Medicine, 2015, 45, 2985-2997.	4.5	38
28	Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). BMC Psychiatry, 2015, 15, 257.	2.6	11
29	Early life trauma, depression and the glucocorticoid receptor gene – an epigenetic perspective. Psychological Medicine, 2015, 45, 3393-3410.	4.5	51
30	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	4.0	528
31	Managing inadequate antidepressant response in depressive illness. British Medical Bulletin, 2015, 115, 183-201.	6.9	17
32	Cortisol awakening response and spatial working memory in man: a Uâ€shaped relationship. Human Psychopharmacology, 2014, 29, 295-298.	1.5	25
33	Somatodendritic 5-hydroxytryptamine sub>1A (sub>(5-HT sub>1A sub>) autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone. Psychological Medicine, 2014, 44, 767-777.	4.5	12
34	Noradrenaline – the forgotten amine?. Journal of Psychopharmacology, 2013, 27, 657-658.	4.0	1
35	A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12Âweeks. Acta Psychiatrica Scandinavica, 2013, 128, 203-211.	4.5	9
36	Metyrapone in treatment-resistant depression. Therapeutic Advances in Psychopharmacology, 2012, 2, 139-149.	2.7	29

#	Article	IF	CITATIONS
37	Author's reply to Letter to the Editor. Journal of Psychopharmacology, 2012, 26, 1164-1164.	4.0	O
38	Effect of low-dose acute tryptophan depletion on the specificity of autobiographical memory in healthy subjects with a family history of depression. Psychopharmacology, 2012, 222, 285-292.	3.1	7
39	The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants. Journal of Psychopharmacology, 2011, 25, 1175-1191.	4.0	66
40	Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology, 2011, 1, 125-127.	2.7	4
41	Hematological Effects of Valproate in Psychiatric Patients. Journal of Clinical Psychopharmacology, 2010, 30, 282-285.	1.4	49
42	The use of antidepressants in clinical practice: focus on agomelatine. Human Psychopharmacology, 2010, 25, 95-102.	1.5	42
43	Lithium in bipolar and other affective disorders: prescribing practice in the UK. Journal of Psychopharmacology, 2010, 24, 1739-1746.	4.0	34
44	Commentary on STAR*D: a summary and UK perspective. Journal of Psychopharmacology, 2009, 23, 615-617.	4.0	0
45	Review: clinically important differences between antidepressants. Evidence-Based Mental Health, 2009, 12, 107-107.	4.5	0
46	Vegetarian psychotropics: a survey of psychotropic medications suitable for vegetarians. Human Psychopharmacology, 2009, 24, 248-249.	1.5	2
47	Do antidepressants work? A commentary on "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al. Evidence-Based Mental Health, 2008, 11, 66-68.	4.5	30
48	Effects of Antidepressant Drugs on Electroencephalography Alpha Power: Importance of Study Duration. Biological Psychiatry, 2008, 64, e5-e6.	1.3	5
49	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2008, 22, 343-396.	4.0	437
50	Birth weight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study. British Journal of Psychiatry, 2008, 192, 333-337.	2.8	130
51	Repeated cortisol administration attenuates the EEG response to buspirone in healthy volunteers: evidence for desensitization of the 5-HT1 A autoreceptor. Journal of Psychopharmacology, 2007, 21, 826-832.	4.0	27
52	A study of the neural correlates of episodic memory and HPA axis status in drug-free depressed patients and healthy controls. Journal of Psychiatric Research, 2007, 41, 295-304.	3.1	17
53	Graduate mental health worker case management of depression in UK primary care: a pilot study. British Journal of General Practice, 2007, 57, 880-885.	1.4	17
54	Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. Journal of Psychopharmacology, 2006, 20, 643-649.	4.0	101

#	Article	IF	CITATIONS
55	Schizophrenia and increased risk of cardiovascular disease. American Heart Journal, 2006, 151, e13.	2.7	10
56	Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology, 2006, 188, 541-551.	3.1	77
57	Managing the aftermath of mania - Newcastle, 2 September 2005: Consensus Meeting Statement. Journal of Psychopharmacology, 2006, 20, 51-54.	4.0	0
58	A case of pancytopenia. Journal of Psychopharmacology, 2006, 20, 690-692.	4.0	9
59	Prescribing of venlafaxine and dosulepin in primary care. Journal of Psychopharmacology, 2006, 20, 868-868.	4.0	2
60	Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam. Evidence-Based Mental Health, 2005, 8, 7-7.	4.5	3
61	Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biological Psychology, 2004, 65, 137-145.	2.2	34
62	EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans. Psychopharmacology, 2003, 166, 284-293.	3.1	26
63	Effects of a single dose of cortisol on the neural correlates of episodic memory and error processing in healthy volunteers. Psychopharmacology, 2003, 167, 431-442.	3.1	63
64	Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. Journal of Psychopharmacology, 2002, 16, 245-252.	4.0	30
65	Rapid tranquillisation: Time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry, 2002, 180, 485-489.	2.8	82
66	Effects of repeated cortisol administration on brain potential correlates of episodic memory retrieval. Psychopharmacology, 2002, 160, 74-83.	3.1	31
67	Effects of tryptophan depletion on brain potential correlates of episodic memory retrieval. Psychopharmacology, 2002, 160, 434-442.	3.1	60
68	Effects of adrenalectomy on 8-OH-DPAT induced hypothermia in mice. Psychopharmacology, 1999, 142, 73-77.	3.1	12
69	Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. Psychopharmacology, 1999, 143, 64-71.	3.1	14
70	Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology, 1999, 146, 194-198.	3.1	19
71	5-Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. Psychopharmacology, 1998, 139, 243-250.	3.1	34
72	Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychological Medicine, 1998, 28, 573-584.	4.5	162

#	Article	IF	CITATIONS
73	Exacerbation of migraine with paroxetine: Case report. Human Psychopharmacology, 1995, 10, 349-350.	1.5	2
74	The temperature dependence of high-threshold calcium channel currents recorded from adult rat dorsal raphe neurones. Neuropharmacology, 1995, 34, 1479-1490.	4.1	21
75	The modulation of calcium channel currents recorded from adult rat dorsal raphe neurones by 5-HT1A receptor or direct G-protein activation. Neuropharmacology, 1995, 34, 1491-1506.	4.1	13